These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25237840)

  • 21. Developing and advancing dry powder inhalation towards enhanced therapeutics.
    Stegemann S; Kopp S; Borchard G; Shah VP; Senel S; Dubey R; Urbanetz N; Cittero M; Schoubben A; Hippchen C; Cade D; Fuglsang A; Morais J; Borgström L; Farshi F; Seyfang KH; Hermann R; van de Putte A; Klebovich I; Hincal A
    Eur J Pharm Sci; 2013 Jan; 48(1-2):181-94. PubMed ID: 23142635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in physical chemistry and dissolution rate of solid particle aerosols from solution pressurised inhalers.
    Buttini F; Miozzi M; Balducci AG; Royall PG; Brambilla G; Colombo P; Bettini R; Forbes B
    Int J Pharm; 2014 Apr; 465(1-2):42-51. PubMed ID: 24491530
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk analysis in bioequivalence and biowaiver decisions.
    Kubbinga M; Langguth P; Barends D
    Biopharm Drug Dispos; 2013 Jul; 34(5):254-61. PubMed ID: 23280474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.
    Wang R; Conner DP; Li BV
    AAPS J; 2017 Mar; 19(2):360-366. PubMed ID: 28004346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe.
    Limberg J; Potthast H
    Biopharm Drug Dispos; 2013 Jul; 34(5):247-53. PubMed ID: 23585295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Best practices for managing quality and safety of foreign particles in orally inhaled and nasal drug products, and an evaluation of clinical relevance.
    Blanchard J; Coleman J; Crim C; Dabreu-Hayling C; Fries L; Ghaderi R; Haeberlin B; Malcolmson R; Mittelman S; Nagao L; Saracovan I; Shtohryn L; Snodgrass-Pilla C; Sundahl M; Wolff R
    Pharm Res; 2007 Mar; 24(3):471-9. PubMed ID: 17252189
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinically relevant test methods to establish in vitro equivalence for spacers and valved holding chambers used with pressurized metered dose inhalers (pMDIs).
    Mitchell J; Dolovich MB
    J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):217-42. PubMed ID: 22857273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delivery Technologies for Orally Inhaled Products: an Update.
    Moon C; Smyth HDC; Watts AB; Williams RO
    AAPS PharmSciTech; 2019 Feb; 20(3):117. PubMed ID: 30783904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patient Focus and Regulatory Considerations for Inhalation Device Design: Report from the 2015 IPAC-RS/ISAM Workshop.
    Roche N; Scheuch G; Pritchard JN; Nopitsch-Mai C; Lakhani DA; Saluja B; Jamieson J; Dundon A; Wallace R; Holmes S; Cipolla D; Dolovich MB; Shah SA; Lyapustina S
    J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):1-13. PubMed ID: 27537608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formulating powder-device combinations for salmeterol xinafoate dry powder inhalers.
    Hassoun M; Ho S; Muddle J; Buttini F; Parry M; Hammond M; Forbes B
    Int J Pharm; 2015 Jul; 490(1-2):360-7. PubMed ID: 25987210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.
    Lee SL; Saluja B; García-Arieta A; Santos GM; Li Y; Lu S; Hou S; Rebello J; Vaidya A; Gogtay J; Purandare S; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1285-304. PubMed ID: 26002510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The dispersion behaviour of dry powder inhalation formulations cannot be assessed at a single inhalation flow rate.
    Grasmeijer F; de Boer AH
    Int J Pharm; 2014 Apr; 465(1-2):165-8. PubMed ID: 24548720
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulatory aspects of modifications to innovator bronchodilator metered dose inhalers and development of generic substitutes.
    Adams WP; Poochikian G; Taylor AS; Patel RM; Burke GP; Williams RL
    J Aerosol Med; 1994; 7(2):119-34. PubMed ID: 10147277
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment methods of inhaled aerosols: technical aspects and applications.
    Jaafar-Maalej C; Andrieu V; Elaissari A; Fessi H
    Expert Opin Drug Deliv; 2009 Sep; 6(9):941-59. PubMed ID: 19637979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Back to the future: inhaled drug products.
    Hickey AJ
    J Pharm Sci; 2013 Apr; 102(4):1165-72. PubMed ID: 23381932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioequivalence assessment of pharmaceutical aerosol products through IVIVC.
    Sandell D
    Adv Drug Deliv Rev; 2021 Sep; 176():113895. PubMed ID: 34329687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Past, Present, and Future of Bioequivalence: Improving Assessment and Extrapolation of Therapeutic Equivalence for Oral Drug Products.
    Cristofoletti R; Rowland M; Lesko LJ; Blume H; Rostami-Hodjegan A; Dressman JB
    J Pharm Sci; 2018 Oct; 107(10):2519-2530. PubMed ID: 29935299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and opportunities in implementing the FDA default parametric tolerance interval two one-sided test for delivered dose uniformity of orally inhaled products.
    Larner G; Cooper A; Lyapustina S; Leiner S; Christopher D; Strickland H; Golden M; Delzeit HJ; Friedman EM
    AAPS PharmSciTech; 2011 Dec; 12(4):1144-56. PubMed ID: 21901649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Best practices for extractables and leachables in orally inhaled and nasal drug products: an overview of the PQRI recommendations.
    Norwood DL; Paskiet D; Ruberto M; Feinberg T; Schroeder A; Poochikian G; Wang Q; Deng TJ; DeGrazio F; Munos MK; Nagao LM
    Pharm Res; 2008 Apr; 25(4):727-39. PubMed ID: 18183477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.